CYTK Insider Transactions — Page 11
1,473 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 1,001–1,100; provenance stays internal.
| Insider profile | Role | Date | Transaction | Shares | Price |
|---|---|---|---|---|---|
| Sabry James H | Executive Chairman | 2009-06-05 | Sale | 5,200.0 | $2.85 |
| Sabry James H | Executive Chairman | 2009-06-05 | Sale | 1,900.0 | $2.84 |
| Sabry James H | Executive Chairman | 2009-06-05 | Sale | 3,500.0 | $2.83 |
| Sabry James H | Executive Chairman | 2009-06-05 | Sale | 100.0 | $2.82 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 1,309.0 | $2.93 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 2,626.0 | $2.92 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 3,065.0 | $2.91 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 1,100.0 | $2.9 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 1,500.0 | $2.89 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 600.0 | $2.88 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 400.0 | $2.87 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 1,356.0 | $2.86 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 3,400.0 | $2.85 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 4,638.0 | $2.84 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 200.0 | $2.84 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 4,062.0 | $2.83 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 3,600.0 | $2.82 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 1,300.0 | $2.81 |
| Sabry James H | Executive Chairman | 2009-06-04 | Sale | 1,044.0 | $2.8 |
| Blum Robert I | President & CEO | 2009-05-22 | Sale | 1,000.0 | $2.0 |
| SCHMERTZLER MICHAEL | Director | 2009-05-21 | Purchase | 1,522,840.0 | $1.97 |
| Blum Robert I | President & CEO | 2009-05-18 | Sale | 1,000.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-05-06 | Sale | 1,000.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-05-01 | Sale | 4,600.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-05-01 | Sale | 76.0 | $2.01 |
| Blum Robert I | President & CEO | 2009-04-24 | Sale | 324.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-04-22 | Sale | 25,200.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-04-21 | Sale | 2,800.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-03-30 | Sale | 2,000.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-03-26 | Sale | 20,000.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-03-17 | Sale | 4,538.0 | $2.0 |
| Blum Robert I | President & CEO | 2009-03-16 | Sale | 962.0 | $2.0 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-03-02 | Sale | 100.0 | $1.61 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-03-02 | Sale | 100.0 | $1.58 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-03-02 | Sale | 900.0 | $1.55 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-03-02 | Sale | 3,700.0 | $1.54 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-03-02 | Sale | 200.0 | $1.52 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 500.0 | $2.19 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 950.0 | $2.17 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 300.0 | $2.16 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 1,050.0 | $2.16 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 300.0 | $2.15 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 500.0 | $2.15 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 500.0 | $2.13 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 400.0 | $2.11 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 400.0 | $2.11 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-02-02 | Sale | 100.0 | $2.07 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 1,125.0 | $2.89 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 847.0 | $2.88 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 900.0 | $2.87 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 400.0 | $2.85 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 200.0 | $2.81 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 300.0 | $2.8 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 128.0 | $2.79 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 100.0 | $2.78 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 288.0 | $2.76 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 312.0 | $2.75 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2009-01-02 | Sale | 400.0 | $2.71 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 100.0 | $2.39 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 200.0 | $2.38 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 100.0 | $2.3 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 100.0 | $2.29 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 460.0 | $2.24 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 700.0 | $2.22 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 429.0 | $2.14 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 211.0 | $2.12 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 1,165.0 | $2.1 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 155.0 | $2.09 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-12-01 | Sale | 1,380.0 | $2.08 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $3.04 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 300.0 | $3.03 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 300.0 | $3.02 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $3.01 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.99 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.98 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.97 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 600.0 | $2.95 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 200.0 | $2.94 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.94 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.93 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.92 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 200.0 | $2.9 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 87.0 | $2.9 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 1,500.0 | $2.89 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 13.0 | $2.87 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.86 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 300.0 | $2.85 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 500.0 | $2.84 |
| MORGANS DAVID J JR | EVP-Preclinical R&D | 2008-11-03 | Sale | 100.0 | $2.83 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 100.0 | $4.78 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 300.0 | $5.01 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 2,100.0 | $5.0 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 3,600.0 | $4.99 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 1,000.0 | $4.96 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 600.0 | $4.93 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 800.0 | $4.92 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 1,700.0 | $4.91 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 1,600.0 | $4.9 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 100.0 | $4.89 |
| Sabry James H | Executive Chairman | 2008-09-26 | Sale | 700.0 | $4.88 |